Keywords: novartis, novo, join, market, nn622, pharma, nordisk
Novartis and Novo join to market NN622
Article | 23 July 2001
Novartis Pharma and Novo Nordisk have reached an agreement, subject toUS regulatory approval, for the commercialization of NN622 (DRF-2725) as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
